BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kidd M, Bodei L, Modlin IM. Chromogranin A: any relevance in neuroendocrine tumors? Curr Opin Endocrinol Diabetes Obes 2016;23:28-37. [PMID: 26627724 DOI: 10.1097/MED.0000000000000215] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mendieta I, Rodríguez-Nieto M, Nuñez-Anita RE, Menchaca-Arredondo JL, García-Alcocer G, Berumen LC. Ultrastructural changes associated to the neuroendocrine transdifferentiation of the lung adenocarcinoma cell line A549. Acta Histochem 2021;123:151797. [PMID: 34688180 DOI: 10.1016/j.acthis.2021.151797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Geisler L, Mohr R, Lambrecht J, Knorr J, Jann H, Loosen SH, Özdirik B, Luedde T, Hammerich L, Tacke F, Wree A, Hellberg T, Roderburg C. The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. Int J Mol Sci 2021;22:8569. [PMID: 34445276 DOI: 10.3390/ijms22168569] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
4 Hinterleitner M, Sipos B, Wagner V, Grottenthaler JM, Lauer UM, Zender L, Hinterleitner C. Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies. Cancers (Basel) 2021;13:2286. [PMID: 34064565 DOI: 10.3390/cancers13102286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yukina MY, Karpova PL, Troshina EA, Platonova NM, Beltsevich DG. Chromogranin A in diagnosis of pheochromocytoma (comparative analysis). Terapevticheskii arkhiv 2021;93:389-96. [DOI: 10.26442/00403660.2021.04.200678] [Reference Citation Analysis]
6 Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord 2021;22:539-52. [PMID: 33783695 DOI: 10.1007/s11154-021-09631-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
8 Pulvirenti A, Pea A, Chang DK, Jamieson NB. Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Front Med (Lausanne) 2020;7:385. [PMID: 32850899 DOI: 10.3389/fmed.2020.00385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
10 McCarthy DM. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship? Int J Mol Sci 2020;21:E662. [PMID: 31963924 DOI: 10.3390/ijms21020662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
11 Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging 2020;47:895-906. [PMID: 31838581 DOI: 10.1007/s00259-019-04601-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
12 Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. [PMID: 31695546 DOI: 10.1177/1179551419884058] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
13 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Matar S, Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, Filosso PL, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Kos-Kudła B, Ćwikła JB, Drozdov IA, Kidd M, Modlin IM. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology 2020;110:185-97. [PMID: 30995665 DOI: 10.1159/000500202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect 2019:EC-19-0030. [PMID: 30865931 DOI: 10.1530/EC-19-0030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
16 Ram P, Penalver JL, Lo KBU, Rangaswami J, Pressman GS. Carcinoid Heart Disease: Review of Current Knowledge. Tex Heart Inst J 2019;46:21-7. [PMID: 30833833 DOI: 10.14503/THIJ-17-6562] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
17 Patel S. Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation. Curr Allergy Asthma Rep 2018;18:63. [PMID: 30267163 DOI: 10.1007/s11882-018-0817-3] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 14.3] [Reference Citation Analysis]
18 Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist 2019;24:783-90. [PMID: 30158287 DOI: 10.1634/theoncologist.2017-0623] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
19 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018;2018:9647247. [PMID: 30140282 DOI: 10.1155/2018/9647247] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zhou Y, Li D, Lin Y, Yu M, Lu X, Jian Z, Na N, Hou B. Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. Onco Targets Ther 2018;11:2489-96. [PMID: 29760558 DOI: 10.2147/OTT.S152657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
21 Al-Risi ES, Al-Essry FS, Mula-Abed WS. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman. Oman Med J. 2017;32:365-370. [PMID: 29026467 DOI: 10.5001/omj.2017.71] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
22 Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect 2016;5:174-87. [PMID: 27582247 DOI: 10.1530/EC-16-0043] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 8.2] [Reference Citation Analysis]